A New Low-Estrogen Contraceptive Option Applied Once Weekly: FDA Approves Gwyn Lo

Remembering to take medication every day is a practical threshold for whether oral contraceptives can be effective. The U.S. Food and Drug Administration (FDA) has approved Viatris’ Gwyn Lo, giving eligible women another reversible, noninvasive option that requires attention only once a week. The patch also reduces daily estrogen delivery to 20 micrograms, seeking to balance convenience with hormone exposure.

Gwyn Lo contains the progestin norelgestromin and the estrogen ethinyl estradiol, delivering 220 micrograms and 20 micrograms per day, respectively. It is used for three consecutive weeks, with the patch replaced weekly, followed by a patch-free fourth week. The 4.86 milligrams and 0.264 milligrams listed in the clinical trial registry refer to the total amounts of the drugs contained in each patch and do not conflict with the approved information specifying the daily delivery doses.

The FDA approved the product through the 505(b)(2) pathway, with the primary evidence coming from the Phase 3 Luminous trial, which lasted up to 13 cycles. ClinicalTrials.gov data show that the study enrolled 1,319 participants and used a multicenter, open-label, single-arm design to assess contraceptive efficacy, menstrual cycle control, safety, tolerability, and patch use.

In the efficacy population aged 18 to 35, the study produced a Pearl Index of 4.14, with a 95% confidence interval of 2.77 to 5.95. This measure represents the number of pregnancies occurring per 100 women during one year of use. Because the study had no parallel control group, the figure should not be interpreted directly as showing superiority over other contraceptive patches or oral contraceptives. Real-world effectiveness may also be affected by factors such as whether the patch is replaced as directed.

Adhesion is another hurdle in ensuring that transdermal contraception works reliably. Viatris reported that, among the 39,790 patches used during the one-year trial, 1.3% detached completely. A separate Phase 1 study tested drug delivery under conditions including sauna use, treadmill exercise, and cold-water bathing. However, these results cannot cover every skin type, climate, and daily activity, and postmarketing real-world data will better reflect long-term performance.

Common adverse reactions include application-site irritation, redness, and itching, as well as unscheduled bleeding, heavy withdrawal bleeding, and nausea. As an estrogen-containing combined hormonal contraceptive, Gwyn Lo is not suitable for everyone. Its approved indication is limited to women of reproductive potential with a BMI below 30 kg/m² who are eligible to use combined contraceptives. It is contraindicated in those with a BMI of 30 kg/m² or higher and in smokers over age 35, with the latter facing a higher risk of serious cardiovascular events.

This approval expands the choice of contraceptive methods rather than providing a single answer suitable for everyone. The patch can reduce the burden of taking a pill every day, but it must still be replaced regularly and does not prevent sexually transmitted infections. Whether it is appropriate for an individual still requires assessment with a healthcare professional based on thrombosis and cardiovascular risks, smoking status, BMI, and medication preferences. Viatris expects to launch Gwyn Lo in the United States later in 2026; pricing and insurance coverage have yet to be announced.